Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1999 1
2003 1
2006 1
2007 1
2009 1
2011 2
2012 2
2013 5
2014 2
2016 5
2017 3
2020 4
2021 3
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Cystic fibrosis foundation consensus statements for the care of cystic fibrosis lung transplant recipients.
Shah P, Lowery E, Chaparro C, Visner G, Hempstead SE, Abraham J, Bhakta Z, Carroll M, Christon L, Danziger-Isakov L, Diamond JM, Lease E, Leonard J, Litvin M, Poole R, Vlahos F, Werchan C, Murray MA, Tallarico E, Faro A, Pilewski JM, Hachem RR. Shah P, et al. Among authors: pilewski jm. J Heart Lung Transplant. 2021 Jul;40(7):539-556. doi: 10.1016/j.healun.2021.04.011. Epub 2021 Apr 22. J Heart Lung Transplant. 2021. PMID: 34103223 Free article. Review.
Cystic fibrosis (CF) is the indication for transplantation in approximately 15% of recipients worldwide, and Cystic Fibrosis Lung Transplant Recipients (CFLTRs) have excellent long-term outcomes. Yet, CFLTRs have unique comorbidities that require specialized care. ...
Cystic fibrosis (CF) is the indication for transplantation in approximately 15% of recipients worldwide, and Cystic Fibrosis Lung Transplant …
Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients.
Ramos KJ, Guimbellot JS, Valapour M, Bartlett LE, Wai TH, Goss CH, Pilewski JM, Faro A, Diamond JM; CFLTC Study Group. Ramos KJ, et al. Among authors: pilewski jm. J Cyst Fibros. 2022 Sep;21(5):745-752. doi: 10.1016/j.jcf.2022.04.009. Epub 2022 Apr 23. J Cyst Fibros. 2022. PMID: 35474016 Free PMC article.
Further study is needed to determine the risks and benefits of ETI in the CF lung transplant population given the potential for drug interactions, side effects leading to discontinuation of ETI, and the possible mechanisms for ETI to positively impact long-term post-transp …
Further study is needed to determine the risks and benefits of ETI in the CF lung transplant population given the potential for drug interac …
Psychiatric Predictors of Long-term Transplant-Related Outcomes in Lung Transplant Recipients.
Rosenberger EM, DiMartini AF, DeVito Dabbs AJ, Bermudez CA, Pilewski JM, Toyoda Y, Dew MA. Rosenberger EM, et al. Among authors: pilewski jm. Transplantation. 2016 Jan;100(1):239-47. doi: 10.1097/TP.0000000000000824. Transplantation. 2016. PMID: 26177087 Free PMC article.
BACKGROUND: Long-term survival after lung transplantation remains poor, yet modifiable risk factors for late-term morbidity and mortality have yet to be identified. ...CONCLUSIONS: Early posttransplant depression increases risk for long-term transplant-relate …
BACKGROUND: Long-term survival after lung transplantation remains poor, yet modifiable risk factors for late-term morbidity an …
Cross-Regulation of F-Box Protein FBXL2 with T-bet and TNF-α during Acute and Chronic Lung Allograft Rejection.
Das A, Wang X, Wei J, Hoji A, Coon TA, Popescu I, Brown M, Frizzell S, Iasella CJ, Noda K, Sembrat JC, Devonshire K, Hannan SJ, Snyder ME, Pilewski JM, Sanchez PG, Chandra D, Mallampalli RK, Alder JK, Chen BB, McDyer JF. Das A, et al. Among authors: pilewski jm. J Immunol. 2022 Nov 1;209(9):1788-1795. doi: 10.4049/jimmunol.2200245. Epub 2022 Sep 16. J Immunol. 2022. PMID: 36113884 Free PMC article.
Chronic lung allograft dysfunction is the major barrier to long-term survival in lung transplant recipients. Evidence supports type 1 alloimmunity as the predominant response in acute/chronic lung rejection, but the immunoregulatory mechanisms remain incompletely understoo …
Chronic lung allograft dysfunction is the major barrier to long-term survival in lung transplant recipients. Evidence supports type 1 …
Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations.
Pilewski JM, De Boeck K, Nick JA, Tian S, DeSouza C, Higgins M, Moss RB. Pilewski JM, et al. Pulm Ther. 2020 Dec;6(2):303-313. doi: 10.1007/s41030-020-00129-2. Epub 2020 Sep 23. Pulm Ther. 2020. PMID: 32965659 Free PMC article.
Initially approved for people with CF (pwCF) with G551D-CFTR gating mutations, ivacaftor demonstrated clinical benefit in pwCF with other gating mutations and certain residual function mutations, including R117H-CFTR, in clinical studies. We evaluated the long-term safety …
Initially approved for people with CF (pwCF) with G551D-CFTR gating mutations, ivacaftor demonstrated clinical benefit in pwCF with other ga …
Type-1 immunity and endogenous immune regulators predominate in the airway transcriptome during chronic lung allograft dysfunction.
Iasella CJ, Hoji A, Popescu I, Wei J, Snyder ME, Zhang Y, Xu W, Iouchmanov V, Koshy R, Brown M, Fung M, Langelier C, Lendermon EA, Dugger D, Shah R, Lee J, Johnson B, Golden J, Leard LE, Ellen Kleinhenz M, Kilaru S, Hays SR, Singer JP, Sanchez PG, Morrell MR, Pilewski JM, Greenland JR, Chen K, McDyer JF. Iasella CJ, et al. Among authors: pilewski jm. Am J Transplant. 2021 Jun;21(6):2145-2160. doi: 10.1111/ajt.16360. Epub 2020 Nov 20. Am J Transplant. 2021. PMID: 33078555 Free PMC article.
Chronic lung allograft dysfunction (CLAD) remains the major complication limiting long-term survival among lung transplant recipients (LTRs). Limited understanding of CLAD immunopathogenesis and a paucity of biomarkers remain substantial barriers for earlier detection and …
Chronic lung allograft dysfunction (CLAD) remains the major complication limiting long-term survival among lung transplant recipients …
Lung transplantation after lung volume reduction surgery.
Shigemura N, Gilbert S, Bhama JK, Crespo MM, Zaldonis D, Pilewski JM, Bermudez CA. Shigemura N, et al. Among authors: pilewski jm. Transplantation. 2013 Aug 27;96(4):421-5. doi: 10.1097/TP.0b013e31829853ac. Transplantation. 2013. PMID: 23736352
We compared in-hospital morbidity, functional capacity, and long-term outcomes of patients who underwent LVRS before lung transplantation with a matched cohort of patients without prior LVRS to assess the influence of LVRS on posttransplantation morbidity and mortality. .. …
We compared in-hospital morbidity, functional capacity, and long-term outcomes of patients who underwent LVRS before lung transplanta …
Long-Term Follow-up of a Randomized Controlled Trial Evaluating a Mobile Health Intervention for Self-Management in Lung Transplant Recipients.
Rosenberger EM, DeVito Dabbs AJ, DiMartini AF, Landsittel DP, Pilewski JM, Dew MA. Rosenberger EM, et al. Among authors: pilewski jm. Am J Transplant. 2017 May;17(5):1286-1293. doi: 10.1111/ajt.14062. Epub 2016 Oct 31. Am J Transplant. 2017. PMID: 27664940 Free PMC article. Clinical Trial.
A randomized controlled trial showed Pocket PATH's superiority to usual care for promoting the self-management behaviors of adherence, self-monitoring and communication with clinicians during posttransplant year 1. Its long-term impact was unknown. In this study, we examin …
A randomized controlled trial showed Pocket PATH's superiority to usual care for promoting the self-management behaviors of adherence, self- …
Impact of a Mobile Health Intervention on Long-term Nonadherence After Lung Transplantation: Follow-up After a Randomized Controlled Trial.
Geramita EM, DeVito Dabbs AJ, DiMartini AF, Pilewski JM, Switzer GE, Posluszny DM, Myaskovsky L, Dew MA. Geramita EM, et al. Among authors: pilewski jm. Transplantation. 2020 Mar;104(3):640-651. doi: 10.1097/TP.0000000000002872. Transplantation. 2020. PMID: 31335759 Free PMC article. Clinical Trial.
We examined whether these effects were maintained beyond the end of the trial and evaluated other potential risk factors for long-term nonadherence. METHODS: Adherence in 8 areas was evaluated at follow-up in separate LTR and family caregiver (collateral) assessments. ...C …
We examined whether these effects were maintained beyond the end of the trial and evaluated other potential risk factors for long-term …
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE; VX14-661-110 study group. Flume PA, et al. Lancet Respir Med. 2021 Jul;9(7):733-746. doi: 10.1016/S2213-2600(20)30510-5. Epub 2021 Feb 10. Lancet Respir Med. 2021. PMID: 33581080
Here, we present results of study 661-110 (EXTEND), a 96-week open-label extension study that assessed long-term safety, tolerability, and efficacy of tezacaftor-ivacaftor in participants aged 12 years or older with cystic fibrosis who were homozygous or heterozygous for t …
Here, we present results of study 661-110 (EXTEND), a 96-week open-label extension study that assessed long-term safety, tolerability …
28 results